Another Three Biosimilar Insulins Planned from Meitheal Pharmaceuticals, Inc.

On September 21, 2023, Chicago-basedMeitheal Pharmaceuticals, Inc. (which is a subsidiary of a Chinese parent company named Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.) announced an exclusive commercial licensing agreement with a different Chinese company known asTonghua Dongbao Pharmaceutical Co. Ltd. with intent to sell three insulin biosimilars in the U.S. market.     The company press release can be seen athttps://www.meithealpharma.com/news/61 while the pharmaceutical industry trade press covered the story athttps://www.thepharmaletter.com/article/licensing-deal-to-bring-three-new-insulin-biosimilars-to-the-usa.Meitheal announced its intent to sell biosimilars of the three bestselling insulin analogues currently sold in the U.S. (for insulin aspart, insulin lispro, and insulin glargine). The company expects to begin clinical trials necessary for the three insulin biosimilars in 2024. Meitheal will be several years later than a number of other companies currently which are have insulin biosimilars pending approval which are forecast to hit the market in 2024.Meitheal Pharmaceuticals will follow a nearly-identical commercialization path to virtually all other insulin biosimilars (exceptions being those from the biggest branded insulin-makers, including Lilly, Sanofi and Novo Nordisk (Lilly sells copies of Sanofi Lantus, and Sanofi sells a copy of Lilly Humalog). Aside from copies made by big branded insulin-makers, all other insulin bi...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 Biosimilar insulin Meitheal Pharmaceuticals Source Type: blogs